Drugs / MKC-1
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00656461 | Mar 2008 → Jul 2009 | cancer of unknown primary site | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00506402 | Nov 2006 → Jan 2009 | myelodysplastic syndrome, myelofibrosis with myeloid metaplasia | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00014365 | Oct 2000 → Oct 2001 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003755 | Oct 1998 → Aug 2001 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00408226 | Oct 2006 → Jun 2009 | non-small cell lung carcinoma | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00607607 | Jan 2008 → Jun 2011 | endometrial cancer, ovarian cancer | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00568646 | Nov 2007 → Apr 2009 | malignant pancreatic neoplasm | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00306631 | Jan 2006 → Apr 2008 | breast cancer | CASI pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00016250 | Dec 2000 → Jun 2002 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MKC-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00506402 ↗ |
| Known as | RO 31-7453 | ChEMBL registry synonym — accepted as the source's own label CHEMBL52885 ↗ |
| Action | Inhibit | “an inhibitor of importin-β, tubulin, and the mTOR pathway” PMID 21800081 ↗ Jul 20113“Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL52885 ↗ “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL52885 ↗ “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL52885 ↗ |
| Modality | Small molecule | — CHEMBL52885 ↗ |
| Route | Oral | “Oral capsules” NCT00306631 ↗ |
| Target | AURKA | “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL52885 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL52885 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL52885 ↗ |